DUBLIN, May 18, 2022--(BUSINESS WIRE)--The "Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
The Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Juvenile Macular Degeneration pipeline landscape.
The guide provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Juvenile Macular Degeneration pipeline guide also reviews of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 7, 1, 14 and 12 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The pipeline guide provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration.
The pipeline guide reviews pipeline therapeutics for Juvenile Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Juvenile Macular Degeneration therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Juvenile Macular Degeneration therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Juvenile Macular Degeneration
Key Topics Covered:
Juvenile Macular Degeneration (Stargardt Disease) - Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Companies Involved in Therapeutics Development
Alkeus Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Alpine Biotherapeutics Corp
Applied Genetic Technologies Corp
Astellas Pharma Inc
Beam Therapeutics Inc
Belite Bio Inc
Brooklyn ImmunoTherapeutics Inc
Copernicus Therapeutics Inc
Curative Biotechnology Inc
Fera Pharmaceuticals LLC
Generation Bio Co
Grupo Ferrer Internacional SA
IVERIC bio Inc
Kubota Vision Inc
Mediphage Bioceuticals Inc
Nanoscope Therapeutics Inc
Oak bay Biosciences Ltd
ProQR Therapeutics NV
Ray Therapeutics Inc
ReVision Therapeutics Inc
Saliogen Therapeutics Inc
Shape Therapeutics Inc
Spark Therapeutics Inc
Splice Bio SL
Stargazer Pharmaceuticals Inc
Juvenile Macular Degeneration (Stargardt Disease) - Drug Profiles
4P-020 - Drug Profile
ALK-001 - Drug Profile
ASP-7317 - Drug Profile
avacincaptad pegol sodium - Drug Profile
BIO-201 - Drug Profile
CDX-301 - Drug Profile
CTxABCA-4 - Drug Profile
emixustat hydrochloride - Drug Profile
FAB-111 - Drug Profile
Gene Therapy 1 to Activate ABCA4 for Stargardt Disease - Drug Profile
Gene therapy for Juvenile Macular Degeneration (Stargardt Disease) - Drug Profile
Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile
GTSG - Drug Profile
Jcell - Drug Profile
metformin - Drug Profile
miniABCA4: STGD1 - Drug Profile
QR-1011 - Drug Profile
RAY-001 - Drug Profile
REV-0100 - Drug Profile
SHP-261 - Drug Profile
soraprazan - Drug Profile
STG-001 - Drug Profile
TFB for Dry Age-Related Macular Degeneration, Stargardt Macular Dystrophy - Drug Profile
tinlarebant - Drug Profile
VMCO-1 - Drug Profile
vutrisiran - Drug Profile
Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects
Juvenile Macular Degeneration (Stargardt Disease) - Product Development Milestones
Featured News & Press Releases
For more information about this report visit https://www.researchandmarkets.com/r/cmh2dx
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005583/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900